Lead: Bloomberg reported that Qiagen is evaluating strategic options, including a potential sale, after talks with multiple potential buyers and advisers. Market analysts and sources cited renewed interest from strategics and private equity as the supervisory board fields preliminary inquiries. The report noted historical precedent—Thermo Fisher’s failed bid in 2020—and commentary from J.P. Morgan’s Casey Woodring that a sale would not surprise investors given Qiagen’s diagnostic assets. Qiagen declined to comment publicly on the outreach. Industry observers flagged implications for consolidation in life‑science tools and diagnostics, noting that any takeover could reshape competition in molecular workflows and infectious‑disease testing. Potential buyers would weigh Qiagen’s product mix, regulatory risk, and integration synergies.